Japan ministry of health, labor and welfare (MHLW) grants marketing approval for olumiant® (baricitinib) for the treatment of rheumatoid arthritis

6th July 2017 Uncategorised 0

Eli Lilly and Company

More: Japan ministry of health, labor and welfare (MHLW) grants marketing approval for olumiant® (baricitinib) for the treatment of rheumatoid arthritis
Source: MDlinx